AGEN - Agenus Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
4.26
-0.07 (-1.62%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.33
Open4.86
Bid4.23 x 200
Ask4.29 x 200
Day's Range4.20 - 4.90
52 Week Range3.20 - 5.91
Volume12,224,921
Avg. Volume1,273,847
Market Cap424.91M
Beta2.92
PE Ratio (TTM)-3.38
EPS (TTM)-1.26
Earnings DateJul 28, 2017 - Jul 31, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.25
Trade prices are not sourced from all markets
  • CNBC10 hours ago

    Cramer Remix: The oil market is alive and may be ready to start kicking

    Jim Cramer drilled into Schlumberger’s stock and what the company’s latest commentary means for the industry as a whole.

  • Cramer Remix: The oil market is alive and may be ready to start kicking
    CNBC10 hours ago

    Cramer Remix: The oil market is alive and may be ready to start kicking

    Jim Cramer drilled into Schlumberger’s stock and what the company’s latest commentary means for the industry as a whole.

  • Why Agenus Inc. Stock Briefly Popped Today
    Motley Fool17 hours ago

    Why Agenus Inc. Stock Briefly Popped Today

    After the market had time to reflect on Agenus' new CAR-T venture, investors were unimpressed by its prospects.

  • Bruno Lucidi Appointed Chief Executive Officer of AgenTus Therapeutics, The Cell Therapy Subsidiary of Agenus
    PR Newswire18 hours ago

    Bruno Lucidi Appointed Chief Executive Officer of AgenTus Therapeutics, The Cell Therapy Subsidiary of Agenus

    LEXINGTON, Mass., Oct. 23, 2017 /PRNewswire/ -- Agenus Inc. (AGEN) Chairman and Chief Executive Officer (CEO) Garo Armen Ph.D. announces the appointment of Bruno Lucidi as CEO of AgenTus Therapeutics, Inc., a subsidiary of Agenus that has been established as a dedicated cell therapy company, which will focus on the discovery, development, and commercialization of Adoptive Cell Therapy (ACT). Lucidi brings extensive expertise in drug development and more than 30 years of experience in the biopharmaceutical industry.

  • Agenus creates New Cell Therapy subsidiary named AgenTus Therapeutics
    PR Newswire21 hours ago

    Agenus creates New Cell Therapy subsidiary named AgenTus Therapeutics

    LEXINGTON, Mass., Oct. 23, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of a subsidiary company for its cell therapy business, AgenTus Therapeutics, Inc. The subsidiary is focused on realizing significant value for both companies, enhancing business focus, speed, and efficiency toward the realization of breakthrough I-O "living drugs" to advance cures for patients with cancer.

  • PR Newswire3 days ago

    FDA Approves GSK's Shingles Vaccine with Agenus' QS-21 Stimulon® Adjuvant

    LEXINGTON, Mass., Oct. 20, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that the US Food and Drug Administration (FDA) granted marketing authorization to GlaxoSmithKline's (GSK) herpes zoster vaccine, SHINGRIX, containing Agenus' proprietary immune adjuvant QS-21 Stimulon®. SHINGRIX is indicated for prevention of herpes zoster (also known as shingles) in adults aged 50 years and older.

  • ACCESSWIRE4 days ago

    Today's Research Reports on Trending Tickers: Agenus and Prana Biotechnology

    NEW YORK, NY / ACCESSWIRE / October 20, 2017 / The Dow Jones and S&P 500 rallied late to close in the green Thursday, which was the 30th anniversary of the 1987 Black Monday stock market crash. The Dow ...

  • Why Agenus Inc. Stock Slumped Today
    Motley Fool4 days ago

    Why Agenus Inc. Stock Slumped Today

    Agenus' $250 million mixed shelf offering caused investors to hit the exits today.

  • CNW Group11 days ago

    SHINGRIX approved in Canada as the first non-live adjuvanted vaccine to help protect against shingles

    MISSISSAUGA, ON , Oct. 13, 2017 /CNW/ - SHINGRIX has been approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older .i   SHINGRIX is a non-live, recombinant subunit ...

  • PR Newswire11 days ago

    GSK's Shingrix Containing Agenus' QS-21 Stimulon® Adjuvant Receives Marketing Authorization from Health Canada

    LEXINGTON, Mass., Oct. 13, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Health Canada granted marketing authorization to GlaxoSmithKline's (GSK) shingles vaccine, Shingrix, that contains Agenus' proprietary immune adjuvant QS-21 Stimulon® adjuvant. The approval in Canada marks the first approval for Shingrix and the first approval of a vaccine containing QS-21 Stimulon.